Prostate cancer patients resistant to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear Medicine. In an exploratory study using a relatively new technique–targeted next-generation gene sequencing–researchers found mutations in six out of seven patients with metastatic castration-resistant prostate cancer who did not respond to (PSMA)-targeted radiopharmaceutical therapy despite sufficient PSMA expression in tumors.
- Custom diets are essential to mental health, new research shows
- Do marketers matter for entrepreneurs?
- A new effect of red ginseng: suppression of lung cancer metastasis
- How are universities planning to tackle emissions associated with food and flying?
- Pressure-regulated excitonic feature enhances photocurrent of all-inorganic 2D perovski